Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Save your unit preferences in settings!

    Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

    Predicts survival based on clinical and laboratory data in metastatic RCC patients.
    Favorite

    INSTRUCTIONS

    • Use baseline factors at the start date of the current line of systemic therapy, except for the “time of diagnosis to systemic therapy” criterion, which is always relative to first-line therapy.

    • Always correct calcium concentration for low albumin before scoring.

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with metastatic RCC undergoing systemic therapy and being considered for clinical trial enrollment, and in clinical practice for the estimation of prognosis.

    • May assist in estimating prognosis of patients with metastatic RCC, but is not currently used for making decisions about treatment (use IMDC Risk Model instead).

    • Easy to use and uses readily available clinical and laboratory variables.

    Assists clinicians in discussions about prognosis for patients with metastatic RCC and can be used as a stratification factor in clinical trials.

    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Management

    The score is currently not used for treatment decision-making. The IMDC Risk Model, which was originally based on the MSKCC/Motzer score, is currently used in treatment decision-making for metastatic RCC (NCCN Guidelines 2019).

    Critical Actions

    Can only be applied to patients with metastatic RCC that receive systemic therapy.

    Content Contributors
    Reviewed By
    • Toni Choueiri, MD
    About the Creator
    Dr. Robert J. Motzer
    Are you Dr. Robert J. Motzer?
    Content Contributors
    Reviewed By
    • Toni Choueiri, MD